We are live on ! Find out more
RGNX icon

Regenxbio

174 hedge funds and large institutions have $593M invested in Regenxbio in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 62 increasing their positions, 60 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

49% more capital invested

Capital invested by funds: $399M → $593M (+$194M)

5% more funds holding

Funds holding: 166174 (+8)

8% more call options, than puts

Call options by funds: $2.83M | Put options by funds: $2.62M

3% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 60

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.6% less ownership

Funds ownership: 81.88%81.28% (-0.6%)

Holders
174
Holders Change
+8
Holders Change %
+4.82%
% of All Funds
2.1%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
62
Reduced
60
Closed
14
Calls
$2.83M
Puts
$2.62M
Net Calls
+$212K
Net Calls Change
+$332K

RGNX Hedge Fund Activity: Q4 2025 in Review

174 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2025, worth a combined $593M — up 49% from $399M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new RGNX positions and 14 closed out — a net gain of 10 holders — while 62 added to existing stakes and 60 trimmed.

The largest buyer was Assenagon Asset Management, adding an estimated $5.67M. The largest seller was BlackRock, cutting an estimated $7.65M.

  • 174 institutional investors held Regenxbio (RGNX) as of Q4 2025, up from 166 in Q3 2025.
  • Funds reported $593M of Regenxbio stock for Q4 2025, up 49% quarter-over-quarter.
  • 24 funds opened new Regenxbio positions in Q4 2025 and 14 closed out, a net change of +10 holders.
  • The largest Regenxbio buyer in Q4 2025 was Assenagon Asset Management, an estimated $5.67M added.
  • The largest Regenxbio seller in Q4 2025 was BlackRock, an estimated $7.65M sold.

Based on aggregated 13F filings for Q4 2025.